Answers are grounded in this paper and cite their sources.
Azoospermia, a severe form of male infertility, lacks non-invasive diagnostic tools for molecular typing. Glycosylation of extracellular vesicles (EVs) has diagnostic potential in various diseases. However, high-sensitivity analysis of EV site-specific N-glycans remains challenging, particularly from microliter biofluids. Here, we develop EVGlyco, an integrated low-input workflow for site-specific N-glycans analysis of EV proteins. EVGlyco yields more intact N-glycopeptide identifications than ultracentrifugation-based workflows and is applicable to seven human biofluids. From seminal plasma, 8,435 EV protein site-specific N-glycans are identified in the discovery cohort, and targeted validation via parallel reaction monitoring (PRM) confirms the panel of MPO-N355-H6N2 and ACP3-N94-H5N4F1 distinguishing obstructive azoospermia (OA) from nonobstructive azoospermia (NOA) with an area under the curve (AUC) of 0.88, while CLU-N374-H10N9 and CLU-N374-H10N9F1 further accurately distinguish three NOA subtypes (hypospermatogenesis: 0.86, maturation arrest: 0.99, and Sertoli cell-only: 0.87). This study supports EV protein site-specific N-glycans as diagnostic signatures for non-invasive molecular typing of azoospermia. This study presents EVGlyco, a low-input platform for site-specific N-glycoproteomic analysis of biofluid EVs. It identifies site-specific N-glycan signatures in seminal plasma EVs that distinguish azoospermia types and nonobstructive subtypes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: